Opexa Therapeutics - Revolution in Cell therapy
Seite 2 von 12 Neuester Beitrag: 24.04.21 23:45 | ||||
| Eröffnet am: | 22.02.13 12:31 | von: Balu4u | Anzahl Beiträge: | 294 |
| Neuester Beitrag: | 24.04.21 23:45 | von: Antjeikwza | Leser gesamt: | 38.375 |
| Forum: | Hot-Stocks | Leser heute: | 8 | |
| Bewertet mit: |  | |||
| Seite: < 1 | | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... 12 > | ||||
http://www.streetinsider.com/Corporate+News/...mpliance/10618656.html
Und ne google Übersetzung gibts gratis dazu:
Wie bereits bekannt gegeben, am 5. Dezember 2014 Opexa Therapeutics (Nasdaq: OPXA) erhielt einen Brief von der Auflistung Qualifikationen Abteilung Personal des NASDAQ Stock Market ("NASDAQ") Mitteilung an die Unternehmen, dass in den letzten 30 aufeinander folgenden Tagen der Geldkurs der Stammaktien des Unternehmens war unter $ 1,00 je Aktie, der Mindestschlussgeldkurs durch die Aufrechterhaltung der Kotierung Anforderungen der NASDAQ Regel 5550 erforderlich geschlossen (a) (2). Das Unternehmen wurde ursprünglich vorgesehenen 180 Kalendertage oder bis 3. Juni 2015, um die Einhaltung der Mindestpreisregel wieder zu erlangen.
Am 1. Juni 2015 hat die Gesellschaft beantragt einen zusätzlichen 180-Tage-Frist, um die Einhaltung der NASDAQ Mindestpreisanforderung zurückzugewinnen, weil Aktien der Gesellschaft hat sich weiter für den Handel unterhalb der 1,00 $ Mindestgebotsschlusskurs. Das Unternehmen glaubt, dass er in Übereinstimmung mit allen anderen NASDAQ Erstnotiz Anforderungen einschließlich der Mindest 5.000.000 $ in Eigenkapital ist. Folglich erwartet das Unternehmen NASDAQ dem Antrag stattgegeben und eine Verlängerung von weiteren 180 Tage gewähren.
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Opexa Therapeutics |
Form 8-K for OPEXA THERAPEUTICS, INC.
4-Jun-2015
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St
Item 3.01. Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing.
As previously disclosed, on December 5, 2014, Opexa Therapeutics, Inc. (the "Company") received a letter from the listing qualifications department staff of the NASDAQ Stock Market ("NASDAQ") notifying the Company that for the last 30 consecutive business days the bid price of the Company's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of NASDAQ listing rule 5550(a)(2). The Company was initially provided 180 calendar days, or until June 3, 2015, to regain compliance with the minimum bid price rule, and on June 1, 2015, the Company requested an additional 180-day grace period to regain compliance with NASDAQ's minimum bid price requirement because the Company's stock has continued to trade below the $1.00 minimum closing bid price.
NASDAQ staff granted the Company's extension request on June 4, 2015, and the Company now has until November 30, 2015 to achieve compliance with this listing standard (i.e., by the Company's common stock maintaining a closing bid price of $1.00 per share or more for a minimum of ten consecutive business days during the additional grace period, or such longer period of time as the NASDAQ staff may require).
While the Company intends to actively monitor the closing bid price of its common stock and consider available alternatives, including implementing a reverse stock split, if necessary, there can be no assurance that the Company will be able to regain compliance. In the event the Company is unable to regain compliance by November 30, 2015, or if it does not meet the other listing standards, NASDAQ staff could provide notice that the Company's common stock will become subject to delisting, and in such event, the Company may request a hearing before the NASDAQ Listing Qualifications Panel.
Warum?
Folgender Artikel soll das Kursziel untermauern:
Merck license deal $25 license fee $195M milestone plus royalties and OPXA retains rights for Japan and
certain manufacturing rights all other applications outside of MS. I was not able to copy the 8K on this computer as ads have taken over the page after clicking link somehow. But according to 8K filed on Feb 5th 2013 I get the impression Merck obviously thinks OPXA drug has big potential as Merck will take on and fund the Ph3 trials as well should ph2 go well. $5m was paid by merck just to enter into option and if option is executed will bring $25 mil more. Obviously with more recent $3 M payment Merck likes the trial data which was last updated in April and another trail data update should be coming sometime in Oct according to OPXA CFO. There does not seem to be an toxicity issues to date like the other approved MS drug for this RRMS that has black box label for cardio toxicity so that is a plus. So assuming Ph2 meets endpoints and has no safety issues it will go into Ph3 next year. Should this drug get approved the royalty rate would be between high single digits to mid teens and if opxa decides to co-fund the Ph3 trail royalty rate would be increased. The potential market for this drug is estimated at $7.5B so should all go well and Merck captures say just 30%
$2.25 B at say 15% royalty to opxa = $337,500,000 + $195M milestone + $25M license plus $8M already paid = 565,500, 000 with $337.5M reoccurring annually. Anyone care to guesstimate what PPS would be should all go well as Merck seems to think is possible.
Siehe Opexa
K8 Filing 05.02.2013
Im Oktober 2016 kommen die Ergebnisse der 2b Studie. Sollte diese erwartend positiv ausfallen, steht diese Aktie nicht nur bei 5 USD. Dennoch schwingt bei einem Biotech-Wert auch immer das Risiko des Scheiterns eines Wirkstoffes mit wobei der Wert nicht selten bis zu 90% einbricht.
Bei Zeiten nicht vergessen auch mal mitzunehmen.
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Opexa Therapeutics |
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Opexa Therapeutics |
*
0.1199
24.97%
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Opexa Therapeutics |